JP2020111586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020111586A5 JP2020111586A5 JP2020042730A JP2020042730A JP2020111586A5 JP 2020111586 A5 JP2020111586 A5 JP 2020111586A5 JP 2020042730 A JP2020042730 A JP 2020042730A JP 2020042730 A JP2020042730 A JP 2020042730A JP 2020111586 A5 JP2020111586 A5 JP 2020111586A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- solvate
- salt
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010067125 Liver injury Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 231100000439 acute liver injury Toxicity 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- -1 pentoxifyllines Substances 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114304P | 2015-02-10 | 2015-02-10 | |
| US62/114,304 | 2015-02-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Division JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020111586A JP2020111586A (ja) | 2020-07-27 |
| JP2020111586A5 true JP2020111586A5 (https=) | 2020-12-17 |
Family
ID=56614560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Expired - Fee Related JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
| JP2020042730A Pending JP2020111586A (ja) | 2015-02-10 | 2020-03-12 | 線維症の治療用のセニクリビロック |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Expired - Fee Related JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180110754A1 (https=) |
| EP (1) | EP3256124B1 (https=) |
| JP (2) | JP6676660B2 (https=) |
| KR (1) | KR20170113596A (https=) |
| CN (1) | CN107405403B (https=) |
| AU (1) | AU2015382376B2 (https=) |
| BR (1) | BR112017016388A2 (https=) |
| CA (1) | CA2975445A1 (https=) |
| ES (1) | ES2864767T3 (https=) |
| HK (1) | HK1247558A1 (https=) |
| IL (1) | IL253617A0 (https=) |
| MX (1) | MX2017010277A (https=) |
| RU (1) | RU2722641C2 (https=) |
| SG (1) | SG11201706028RA (https=) |
| WO (1) | WO2016130179A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030329A1 (es) | 2001-08-08 | 2003-05-12 | Takeda Chemical Industries Ltd | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
| JP6716568B2 (ja) | 2014-12-23 | 2020-07-01 | トビラ セラピューティクス， インコーポレイテッド | セニクリビロックの製造方法及び関連類似体 |
| JP2019520427A (ja) | 2016-06-21 | 2019-07-18 | トビラ セラピューティクス， インコーポレイテッド | 精製されたセニクリビロク及びセニクリビロク製造のための精製された中間体 |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
| CN116270633A (zh) * | 2023-03-03 | 2023-06-23 | 神经肌肉骨骼再生医学中心有限公司 | 马拉韦罗在制备治疗肌肉退行性疾病的药物中的用途 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2249027A (en) * | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
| PE20030329A1 (es) | 2001-08-08 | 2003-05-12 | Takeda Chemical Industries Ltd | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
| WO2006059716A1 (ja) | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| WO2013000922A1 (en) * | 2011-06-27 | 2013-01-03 | Universite Pierre Et Marie Curie (Paris 6) | Ccr2 antagonist peptides |
| JP6263815B2 (ja) * | 2013-03-05 | 2018-01-24 | 国立大学法人 岡山大学 | 細胞死抑制剤及びその製造方法 |
| CN105263498B (zh) * | 2013-05-15 | 2019-04-26 | 妥必徕疗治公司 | 赛尼克韦罗组合物及其制备和使用方法 |
| KR101669124B1 (ko) * | 2013-07-11 | 2016-10-25 | 서울대학교병원 | 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물 |
-
2015
- 2015-09-22 BR BR112017016388-8A patent/BR112017016388A2/pt not_active Application Discontinuation
- 2015-09-22 MX MX2017010277A patent/MX2017010277A/es unknown
- 2015-09-22 CN CN201580076576.9A patent/CN107405403B/zh not_active Expired - Fee Related
- 2015-09-22 WO PCT/US2015/051467 patent/WO2016130179A1/en not_active Ceased
- 2015-09-22 US US15/549,958 patent/US20180110754A1/en not_active Abandoned
- 2015-09-22 JP JP2017560462A patent/JP6676660B2/ja not_active Expired - Fee Related
- 2015-09-22 CA CA2975445A patent/CA2975445A1/en not_active Abandoned
- 2015-09-22 RU RU2017130289A patent/RU2722641C2/ru active
- 2015-09-22 SG SG11201706028RA patent/SG11201706028RA/en unknown
- 2015-09-22 EP EP15882259.3A patent/EP3256124B1/en not_active Not-in-force
- 2015-09-22 ES ES15882259T patent/ES2864767T3/es active Active
- 2015-09-22 HK HK18106984.5A patent/HK1247558A1/zh unknown
- 2015-09-22 KR KR1020177023821A patent/KR20170113596A/ko not_active Ceased
- 2015-09-22 AU AU2015382376A patent/AU2015382376B2/en not_active Expired - Fee Related
-
2017
- 2017-07-23 IL IL253617A patent/IL253617A0/en unknown
-
2019
- 2019-02-26 US US16/285,867 patent/US20190343806A1/en not_active Abandoned
-
2020
- 2020-03-12 JP JP2020042730A patent/JP2020111586A/ja active Pending
- 2020-06-03 US US16/891,979 patent/US20200360347A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020111586A5 (https=) | ||
| JP2018505218A5 (https=) | ||
| JP2017105763A5 (https=) | ||
| JP2022058688A5 (https=) | ||
| JP2019501226A5 (https=) | ||
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2018168191A5 (https=) | ||
| RU2017130289A (ru) | Ценикривирок для лечения фиброза | |
| BR112013032770A2 (pt) | composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase | |
| JP2018503685A5 (https=) | ||
| JP2014511374A5 (https=) | ||
| JP2011506412A5 (https=) | ||
| JP2020535225A5 (https=) | ||
| AU2014235273A2 (en) | Treatment of psoriatic arthritis using apremilast | |
| ME00685B (me) | Preparati za tretiranje i prevenciju arterijske tromboze i korišćenje inhibitora faktora xa samog ili u kombinaciji sa plateletnim antiagregacionim agensom | |
| JP2021522247A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| JP2017508817A5 (https=) | ||
| JP2021535175A5 (https=) | ||
| SA521422467B1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| JP2022028975A5 (https=) | ||
| RU2019101226A (ru) | Ингибиторы wnt для применения при лечении фиброза | |
| CO2026000726A2 (es) | Una forma farmacéutica sólida de dosificación bucodispersable de safinamida | |
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions |